UBS Group
TNGX icon

UBS Group’s Tango Therapeutics TNGX Stock Holding History

UBS Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Sell
383,694
-315,658
-45% -$7.8M ﹤0.01% 3252
2026
Q1 		$14.6M Sell
699,352
-291,106
-29% -$4.05M ﹤0.01% 2928
2025
Q4 		$8.78M Buy
990,458
+829,980
+517% +$7.15M ﹤0.01% 3428
2025
Q3 		$1.35M Sell
160,478
-116,624
-42% -$789K ﹤0.01% 5308
2025
Q2 		$1.42M Buy
277,102
+123,767
+81% +$306K ﹤0.01% 5138
2025
Q1 		$210K Sell
153,335
-261,138
-63% -$641K ﹤0.01% 6528
2024
Q4 		$1.28M Sell
414,473
-26,358
-6% -$122K ﹤0.01% 5121
2024
Q3 		$3.39M Buy
440,831
+289,516
+191% +$2.76M ﹤0.01% 3455
2024
Q2 		$1.3M Sell
151,315
-6,911
-4% -$53.4K ﹤0.01% 4178
2024
Q1 		$1.26M Buy
+158,226
New +$1.7M ﹤0.01% 4407
2023
Q4 		– Sell
-30,988
Closed -$349K – 9889
2023
Q3 		$349K Sell
30,988
-147
-0.5% -$896 ﹤0.01% 4933
2023
Q2 		$103K Buy
31,135
+10,643
+52% +$38.3K ﹤0.01% 5986
2023
Q1 		$80.9K Buy
20,492
+4,031
+24% +$23.4K ﹤0.01% 6096
2022
Q4 		$119K Buy
+16,461
New +$116K ﹤0.01% 5942
2022
Q3 		– Sell
-19,225
Closed -$87K – 10929
2022
Q2 		$87K Buy
19,225
+17,175
+838% +$104K ﹤0.01% 5533
2022
Q1 		$16K Sell
2,050
-534
-21% -$4.63K ﹤0.01% 7755
2021
Q4 		$28K Buy
+2,584
New +$31.1K ﹤0.01% 7462
2021
Q3 		– Sell
-3,259
Closed -$37K – 10089
2021
Q2 		$37K Buy
3,259
+460
+16% +$5.17K ﹤0.01% 6726
2021
Q1 		$31K Buy
2,799
+1,651
+144% +$19K ﹤0.01% 6992
2020
Q4 		$13K Sell
1,148
-150
-12% -$1.58K ﹤0.01% 7294
2020
Q3 		$13K Buy
+1,298
New +$13.3K ﹤0.01% 6649

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS Group's TNGX Position: Q2 2026 in Review

UBS Group reduced its Tango Therapeutics (TNGX) stake by 45% in Q2 2026, selling an estimated $7.8M and leaving 383,694 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #3252.

UBS Group first reported a position in TNGX in Q3 2020 and has held it in 21 quarters since. The position peaked at $14.6M in Q1 2026. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • UBS Group held 383,694 shares of Tango Therapeutics worth $12M as of Q2 2026.
  • UBS Group sold 315,658 Tango Therapeutics shares in Q2 2026, an estimated $7.8M.
  • Tango Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3252 holding.
  • UBS Group first reported a position in Tango Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • UBS Group's Tango Therapeutics position peaked at $14.6M in Q1 2026.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.